News
Press Releases

Tuesday, March 22, 2016

CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center

WASHINGTON, D.C — March 22, 2016 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, welcomes MedStar Washington Hospital Center as the newest site for its Phase IIa chronic heart failure (HF) clinical trial. Participant recruitment is underway at this and four other research centers, including Emory…
Read Entire Article

Wednesday, December 16, 2015

CardioCell Appoints Timothy Brown, J.D., as Vice President of Intellectual Property

SAN DIEGO — Dec. 16, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, today welcomes Timothy M. Brown, J.D., as its vice president of intellectual property. This news occurs when CardioCell is advancing at a rapid pace, having recently announced intention to proceed with Phase…
Read Entire Article

Tuesday, December 1, 2015

CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure

SAN DIEGO — Dec. 1, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, intends to proceed with finalizing a Phase IIb clinical trial protocol based on recommendations from a Heart Failure Advisory Board comprising cardiology key opinion leaders and its Scientific Advisory Board members. In…
Read Entire Article

Monday, November 16, 2015

CardioCell CEO Presents at the World Congress of Regenerative Medicine & Stem Cell – Shanghai 2015

SHANGHAI, CHINA – WORLD CONGRESS OF REGENERATIVE MEDICINE & STEM CELL 2015 – Nov. 16, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces a presentation by CEO Sergey Sikora, Ph.D., at the World Congress of Regenerative Medicine & Stem Cell (RMSC) 2015 in Shanghai,…
Read Entire Article

Wednesday, October 28, 2015

CardioCell CEO Presents at BIO-Europe 2015

MUNICH, GERMANY – BIO-EUROPE 2015 – Oct. 28, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces a presentation by CEO Sergey Sikora, Ph.D., at BIO-Europe 2015 in Munich, Germany, Nov. 2-4. The session on Nov. 3 at 9 a.m. illustrates how CardioCell’s ischemia-tolerant mesenchymal…
Read Entire Article

Wednesday, October 21, 2015

CardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine

SAN DIEGO — Oct. 21, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces that collaboration between several scientific board members and principal investigators from its clinical trial sites resulted in a peer-reviewed publication now available in the Journal of Cardiovascular Medicine. Entitled “Rational and…
Read Entire Article

Tuesday, September 1, 2015

CardioCell Scientific Advisory Board Chair Presents at the Stem Cells & Regenerative Medicine Congress 2015

WASHINGTON, D.C. – STEM CELLS & REGENERATIVE MEDICINE CONGRESS 2015 – Sept. 1, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces a presentation by noted cardiologist Dr. Stephen Epstein, the company’s Scientific Advisory Board chair, as well as director, translational and vascular biology research…
Read Entire Article

Tuesday, March 10, 2015

CardioCell Adds Stony Brook University to Sites Conducting a Phase IIa Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure

STONY BROOK, NEW YORK — March 10, 2015 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that designs allogeneic stem-cell therapies for cardiovascular indications, expands patient recruitment to Stony Brook University’s Heart Institute for its Phase IIa clinical trial for chronic heart failure (HF). Recruitment for 20 qualified patients is currently underway at only…
Read Entire Article

Thursday, November 20, 2014

University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy to Treat Chronic Heart Failure (HF) Due to Non-Ischemic Cardiomyopathy

PHILADELPHIA — Nov. 20, 2014 — CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, announces the treatment of its first patient in the University of Pennsylvania’s Phase IIa clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy. The trial, “Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to…
Read Entire Article

Monday, September 8, 2014

CardioCell Scientific Advisory Board Chair Debates in “Strategies for Cardiovascular Repair” Didactic Science Symposium at TCT2014

WASHINGTON, D.C. – TCT2014 – Sept. 8, 2014 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, announces TCT2014 debate participation by prominent cardiologist Dr. Stephen Epstein, the company’s Scientific Advisory Board chair, as well as director, translational and vascular biology research at MedStar Heart Institute and…
Read Entire Article
Older Entries » « Newer Entries